November 18, 2016 - By Linda Rogers · 0 Comments
SCYNEXIS INC (NASDAQ:SCYX) institutional sentiment decreased to 0.76 in Q2 2016. Its down -1.06, from 1.82 in 2016Q1. The ratio worsened, as 20 active investment managers increased and opened new stock positions, while 11 reduced and sold stock positions in SCYNEXIS INC. The active investment managers in our partner’s database now own: 13.69 million shares, up from 8.46 million shares in 2016Q1. Also, the number of active investment managers holding SCYNEXIS INC in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 7 Increased: 10 New Position: 10.
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The company has a market cap of $87.58 million. The Firm is developing its lead product candidate, SCY-078, as an oral and intravenous drug for the treatment of several fungal infections, including serious invasive fungal infections. It currently has negative earnings. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.
About 163,012 shares traded hands. SCYNEXIS Inc (NASDAQ:SCYX) has declined 14.93% since April 18, 2016 and is downtrending. It has underperformed by 19.36% the S&P500.
According to Zacks Investment Research, “SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina.”
Armistice Capital Llc holds 0.58% of its portfolio in SCYNEXIS Inc for 698,000 shares. Dafna Capital Management Llc owns 266,904 shares or 0.46% of their US portfolio. Moreover, Broadfin Capital Llc has 0.31% invested in the company for 1.48 million shares. The Massachusetts-based Granite Point Capital Management L.P. has invested 0.16% in the stock. Deerfield Management Co, a New York-based fund reported 1.77 million shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 5 insider buys, and 0 insider sales for $234,683 net activity.
Ratings analysis reveals 100% of Scynexis Inc’s analysts are positive. Out of 6 Wall Street analysts rating Scynexis Inc, 6 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $8.0 while the high is $17. The stock’s average target of $14.20 is 293.35% above today’s ($3.61) share price. SCYX was included in 9 notes of analysts from August 20, 2015. The firm earned “Strong Buy” rating on Friday, October 7 by WBB Securities. As per Tuesday, December 29, the company rating was initiated by WBB Securities. The firm earned “Buy” rating on Thursday, August 20 by Needham. The rating was maintained by RBC Capital Markets on Monday, November 16 with “Outperform”. The stock has “Buy” rating given by H.C. Wainwright on Thursday, October 20. The firm earned “Buy” rating on Tuesday, August 9 by WBB Securities. The stock of SCYNEXIS Inc (NASDAQ:SCYX) has “Buy” rating given on Wednesday, August 17 by Guggenheim. The rating was initiated by Brean Capital with “Buy” on Monday, March 28. The rating was initiated by Brean Capital with “Buy” on Monday, October 3.
SCYNEXIS, Inc., incorporated on November 4, 1999, is a pharmaceutical company, which is engaged in the discovery, development and commercialization of anti-infectives to address unmet therapeutic needs. The Firm is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. It also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. Candida and Aspergillus species are the fungi responsible for all invasive fungal infections in the United States and Europe. The Firm has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078.
More news for SCYNEXIS Inc (NASDAQ:SCYX) were recently published by: Marketwatch.com, which released: “SCYNEXIS Inc. NASDAQ: SCYX” on April 23, 2014. Globenewswire.com‘s article titled: “SCYNEXIS, Inc. Reports Third Quarter 2016 Financial Results and Provides …” and published on November 07, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Linda Rogers